Cipla is currently trading at Rs. 547.65, up by 5.50 points or 1.01% from its previous closing of Rs. 542.15 on the BSE.
The scrip opened at Rs. 543.00 and has touched a high and low of Rs. 550.75 and Rs. 541.75 respectively. So far 31961 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 621.90 on 06-Feb-2017 and a 52 week low of Rs. 479.00 on 26-May-2017.
Last one week high and low of the scrip stood at Rs. 552.45 and Rs. 536.10 respectively. The current market cap of the company is Rs. 43995.51 crore.
The promoters holding in the company stood at 37.48%, while institutions and non-institutions held 36.05% and 26.47% respectively.
Cipla and Swiss giant Novartis are reportedly in preliminary talks to jointly market asthma drug Xolair, just months after they ended a legal battle over another respiratory drug. Xolair (omalizumab) is an injectable prescription medicine used to treat moderate to severe persistent asthma in patients whose symptoms are not controlled by inhaled corticosteroids.
Cipla lost its battle with Novartis in March, when the Delhi High Court stayed the company’s request to sell copies of Novartis respiratory brand Onbrez (indacaterol).
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For 80 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 100 countries.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1620.50 |
Dr. Reddys Lab | 6171.85 |
Cipla | 1494.65 |
Zydus Lifesciences | 1013.75 |
Lupin | 1617.85 |
View more.. |